Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
While first-line EV plus pembrolizumab has significant health benefits compared to chemotherapy for patients with previously untreated la/mUC, this regimen is not cost-effective at the current price in the United States or China.
Authors
- Youwen Zhu (ORCID: https://orcid.org/0000-0001-8692-3591)
- Hong Zhu (ORCID: https://orcid.org/0009-0000-8919-6203)
- Dan Yuan (ORCID: https://orcid.org/0000-0002-4816-0842)
- Shan Li (ORCID: https://orcid.org/0000-0002-8457-3994)
- Kun Liu (ORCID: https://orcid.org/0000-0001-6720-3310)
Institutions
- Central South University (CN)
- Zhuzhou Central Hospital (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359241295544
- Citations
- 7
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 14.04
Funders
- Xiangya Hospital, Central South University